Anzeige
Mehr »
Login
Donnerstag, 16.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Löst diese riesige Entdeckung die Kupferkrise der KI? So ändert sich die Rechnung durch diesen Explorer!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DZXP | ISIN: US84757R2085 | Ticker-Symbol:
Branche
Internet
Aktienmarkt
Sonstige
1-Jahres-Chart
SPECTRAL CAPITAL CORP Chart 1 Jahr
5-Tage-Chart
SPECTRAL CAPITAL CORP 5-Tage-Chart
ACCESSWIRE
229 Leser
Artikel bewerten:
(1)

Spectral Capital Corp.: Spectral Capital Files Critical Quantum Cybersecurity Patent; Protects Global Encryption from Quantum Threat

Finanznachrichten News

SEATTLE, WA / ACCESSWIRE / January 15, 2025 / Spectral Capital Corporation (OTCQB:FCCN), a pioneer in providing its deep quantum technology platform, is pleased to announce the filing of a critical patent in quantum cybersecurity.

"Over the past three decades, I have been deeply involved in the cybersecurity industry, including founding a leading-edge company that addressed some of the most complex challenges in the field," said Sean Michael Brehm, chairman of Spectral. "Quantum computing elevates cybersecurity risks to an entirely new level. With its potential to break RSA encryption - the foundation of global data security - quantum technology presents an unprecedented threat. In response, our team has developed a solution to ensure RSA encryption remains secure, even in the quantum era." Concluded Spectral chairman Sean Michael Brehm.

"Out of the 104 patentable innovations acquired in the Vogon Cloud acquisition, the patent application around protecting RSA encryption from quantum hacking could be one of our most important. According to Allied Market Research, the global RSA encryption market, primarily measured within the broader "hardware encryption" category, is estimated to hold a significant share, with some reports stating that the RSA segment represents around 50% of the hardware encryption market, which is projected to reach a size of approximately $1.2 trillion by 2031, indicating a substantial market for RSA encryption alone. We are proud to be a part of protecting that market, even as new technologies for encryption emerge, like Spectral's unhackable distributed quantum ledger database technology." Said Spectral's Chief Executive Officer, Jenifer Osterwalder.

Spectral has a portfolio of patents and trade secrets designed to meet the enormous demand for hybrid computing systems which combine current classical computing technologies with emerging quantum computing technologies as these are made commercially available. An entire ecosystem of hardware and software will be needed to support hybrid and quantum computing and Spectral has ambitious plans to build one of the largest intellectual property portfolios in the industry, including its previously announced goal of filing for more than 500 patents by the end of 2025.

About Spectral Capital
Spectral Capital (OTCQB:FCCN) is a quantum technology platform company at the forefront of innovation. Focusing on sustainable green cloud computing, quantum databases, and advanced quantum chip technology, Spectral Capital is revolutionizing industries such as telecommunications, AI, and green technology. With flagship offerings like the Vogon Cloud and Vogon DQLDB, the company is pioneering a future of decentralized, secure, and scalable computing.

Forward-Looking Statements

This press release contains forward-looking statements (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events and FCCN's growth and business strategy. Words such as "expects," "will," "intends," "plans," "believes," "anticipates," "hopes," "estimates," and variations on such words and similar expressions are intended to identify forward-looking statements. Although FCCN believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates that are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of FCCN. Actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, changes in FCCN's business; competitive factors in the market(s) in which FCCN operates; risks associated with operations outside the United States; and other factors listed from time to time in FCCN's filings with the Securities and Exchange Commission. FCCN expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in FCCN's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

For more information, please visit www.spectralcapital.com.

Media Contact:
Stephen Francy
Rubenstein Public Relations
sfrancy@rubensteinpr.com

SOURCE: Spectral Capital Corp.



View the original press release on accesswire.com

© 2025 ACCESSWIRE
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.